ARCHIVES

FDA Approves New Toxicology Protocol; Drug Program Under Fire; DCT Board Approves Cutbacks, Contract Concepts

This article is from The Cancer Letter archive.

Vol. 07 No. 41 | October 9, 1981

Download PDF Visit The Full Archive

Related Articles

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

October 26, 2012

Executive Branch Should Improve Science Pay, NAS Says

July 16, 1993

OAM Director Jacobs To Leave; Cites “Conflict with Conscience”

July 15, 1994

Funding Opportunities: NIH seeks “visionary thinkers” for awards of $2.5 million over five years. NCI RFA available.

January 23, 2004

Group Opposes Bill To Allow Drug Sales After Phase I.

May 26, 2006

Conversation with The Cancer Letter: McKinsey Charge: Create Plan To Expand MD Anderson’s Reach

February 7, 2014